26 March 2019
EMA/154324/2019
EMEA/H/C/002633

Public statement

Vantobra

Withdrawal of the marketing authorisation in the European Union

On 18 February 2019, the European Commission withdrew the marketing authorisation for Vantobra (tobramycin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, PARI Pharma GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Vantobra was granted marketing authorisation in the EU on 18 March 2015 for the management of chronic pulmonary infection due to *Pseudomonas aeruginosa* in patients aged 6 years and older with cystic fibrosis. The marketing authorisation was initially valid for a 5-year period.

Vantobra is an identical product to Tobramycin PARI, which is authorised in the EU for the same condition.

The European Public Assessment Report (EPAR) for Vantobra will be updated to reflect the fact that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union